Literature DB >> 10602726

Penetration of rufloxacin into the cerebrospinal fluid in patients with inflamed and uninflamed meninges.

M V Moretti1, S Pauluzzi, M Cesana.   

Abstract

Forty-four patients scheduled for lumbar puncture (LP) were recruited to determine the level of penetration of orally administered rufloxacin into cerebrospinal fluid (CSF). The patients were divided into three clinical groups: those with normal CSF (groups A(1d) and A(7d)), those with aseptic meningitis (group B), and those with bacterial meningitis (group C). Members of group A(1d) received a single 400-mg rufloxacin dose, while group A(7d), B, and C constituents had a multiple-dose regimen (one 400-mg dose, followed by one 200-mg dose daily for 6 days). LP was performed on group A(1d) members 5 h after they had received treatment, while for group A(7d) it was undertaken 5 h after administration of the last dose. For group B, LP was performed 5 h after the first and the last doses, whereas for group C it was undertaken after the first, fourth, and last doses. Concentrations of rufloxacin in simultaneously collected CSF and plasma samples were determined. Mean CSF/plasma rufloxacin concentration ratios ranged from 0.57 to 0.84, depending on the study group. A higher, but not statistically significant, degree of penetration into CSF was observed in patients with bacterial meningitis than in those with normal CSF or aseptic meningitis. These data indicate that rufloxacin diffuses efficiently into the CSF of patients with either inflamed or uninflamed meninges.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10602726      PMCID: PMC89631          DOI: 10.1128/AAC.44.1.73-77.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  General principles of therapy of pyogenic meningitis.

Authors:  M G Täuber; M A Sande
Journal:  Infect Dis Clin North Am       Date:  1990-12       Impact factor: 5.982

2.  Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent.

Authors:  R Wise; J Johnson; N O'Sullivan; J M Andrews; B P Imbimbo
Journal:  J Antimicrob Chemother       Date:  1991-12       Impact factor: 5.790

Review 3.  Fluoroquinolone antimicrobial agents.

Authors:  D C Hooper; J S Wolfson
Journal:  N Engl J Med       Date:  1991-02-07       Impact factor: 91.245

4.  In vitro activity of a new quinolone, rufloxacin, against nosocomial isolates.

Authors:  R Mattina; C E Cocuzza; M Cesana; G Bonfiglio
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

5.  Penetration of ciprofloxacin into cerebrospinal fluid of patients with bacterial meningitis.

Authors:  M Wolff; L Boutron; E Singlas; B Clair; J M Decazes; B Regnier
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

Review 6.  The penetration of antibiotics into cerebrospinal fluid and brain tissue.

Authors:  R W Barling; J B Selkon
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

7.  Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers.

Authors:  B P Imbimbo; G Broccali; M Cesana; F Crema; G Attardo-Parrinello
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

8.  The in-vitro activity of two new quinolones: rufloxacin and MF 961.

Authors:  R Wise; J M Andrews; R Matthews; M Wolstenholme
Journal:  J Antimicrob Chemother       Date:  1992-06       Impact factor: 5.790

9.  Post-marketing surveillance of quinolones 1988-1990.

Authors:  P G Davey; T McDonald; G Lindsay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-04       Impact factor: 3.267

10.  Steady-state pharmacokinetics of rufloxacin in elderly patients with lower respiratory tract infections.

Authors:  R Cogo; R Rimoldi; R Mattina; B P Imbimbo
Journal:  Ther Drug Monit       Date:  1992-02       Impact factor: 3.681

View more
  3 in total

1.  Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.

Authors:  Julie B Dumond; Rosa F Yeh; Kristine B Patterson; Amanda H Corbett; Byung Hwa Jung; Naser L Rezk; Arlene S Bridges; Paul W Stewart; Myron S Cohen; Angela D M Kashuba
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

2.  Adverse drug reactions related to the use of fluoroquinolone antimicrobials: an analysis of spontaneous reports and fluoroquinolone consumption data from three italian regions.

Authors:  Roberto Leone; Mauro Venegoni; Domenico Motola; Ugo Moretti; Valentina Piazzetta; Alfredo Cocci; Domenico Resi; Federico Mozzo; Giampaolo Velo; Liliana Burzilleri; Nicola Montanaro; Anita Conforti
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

3.  A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis.

Authors:  Emilia Ghelardi; Arianna Tavanti; Paola Davini; Francesco Celandroni; Sara Salvetti; Eva Parisio; Enrico Boldrini; Sonia Senesi; Mario Campa
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.